Aurisco PharmaceuticalLtd Future Growth
Future criteria checks 5/6
Aurisco PharmaceuticalLtd is forecast to grow earnings and revenue by 24% and 23.2% per annum respectively. EPS is expected to grow by 24% per annum. Return on equity is forecast to be 19.2% in 3 years.
Key information
24.0%
Earnings growth rate
24.0%
EPS growth rate
Pharmaceuticals earnings growth | 17.9% |
Revenue growth rate | 23.2% |
Future return on equity | 19.2% |
Analyst coverage | Low |
Last updated | 03 Jun 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,486 | 629 | N/A | 575 | 2 |
12/31/2025 | 2,144 | 515 | N/A | 439 | 3 |
12/31/2024 | 1,677 | 393 | N/A | 340 | 3 |
3/31/2024 | 1,296 | 326 | -9 | 395 | N/A |
12/31/2023 | 1,263 | 289 | 80 | 386 | N/A |
9/30/2023 | 1,162 | 257 | 80 | 367 | N/A |
6/30/2023 | 1,052 | 190 | 9 | 242 | N/A |
3/31/2023 | 1,091 | 216 | 14 | 221 | N/A |
12/31/2022 | 1,008 | 211 | -50 | 166 | N/A |
9/30/2022 | 983 | 222 | -122 | 130 | N/A |
6/30/2022 | 911 | 202 | -82 | 185 | N/A |
3/31/2022 | 836 | 177 | -52 | 203 | N/A |
12/31/2021 | 803 | 169 | -49 | 202 | N/A |
9/30/2021 | 767 | 151 | -15 | 171 | N/A |
6/30/2021 | 741 | 137 | -10 | 172 | N/A |
3/31/2021 | 727 | 140 | 34 | 220 | N/A |
12/31/2020 | 721 | 157 | 56 | 214 | N/A |
9/30/2020 | 688 | 206 | 143 | 255 | N/A |
12/31/2019 | 582 | 186 | 107 | 180 | N/A |
12/31/2018 | 575 | 137 | 16 | 110 | N/A |
12/31/2017 | 544 | 45 | N/A | 118 | N/A |
12/31/2016 | 590 | 87 | N/A | 188 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 605116's forecast earnings growth (24% per year) is above the savings rate (2.9%).
Earnings vs Market: 605116's earnings (24% per year) are forecast to grow faster than the CN market (22.7% per year).
High Growth Earnings: 605116's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 605116's revenue (23.2% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 605116's revenue (23.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 605116's Return on Equity is forecast to be low in 3 years time (19.2%).